Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by DollarMasteron Feb 22, 2012 12:26pm
327 Views
Post# 19567220

ot) 2x NDA filing+ Profitability in 2012 (Mcap 24

ot) 2x NDA filing+ Profitability in 2012 (Mcap 24

BIG PARTNERSHIPS NEWS THIS Q + PROFITABILITY IN THIS YEAR = A LIFETIME OPPORTUNITY HERE .THE MOST INVESTORS STILL NOT REALIZE THE POTENTIAL IN THIS LOW FLOAT MONSTER .GLTA


Partnership news THIS Q and 2 new NDA filings later this year !!!
9 drugs in Pipeline including a Blockbuster all these drugs will be on the Market within 2-3 years !

Burn rate is only 1.2 M a year = cash untill late 2015 EXCLUDING upfront payments from upcoming Partnerships and EXCLUDING cpi-300 revenue.

Price Target : $3-5 within 12-18 Months ! Please do your own DD and realize the MONSTER POTENTIAL in this Goldmine !


Intelgenx (IGX.V)

Market Cap : $ 23.1 M
Cash: $ 4.3 M
Price : 0.50 $


NO DEBT

Shares Out : 45 M ( 23 M shares are held by Insiders + Institutions)


HEAVY BUYING BY INSTITUTIONS
https://data.cnbc.com/quotes/IGXT.OB/tab/8


Burn-rate only 300K per Q / IGXT has 4.3 M cash / Do the Math !
https://images.investorshub.advfn.com/images/uploads/2012/1/11/yimmbslide0004_image006.jpg



PARTNERDEAL THIS QUARTER
https://images.investorshub.advfn.com/images/uploads/2012/1/11/wliylslide0009_image018.jpg


Sales Potential for approved drug CPI-300
https://images.investorshub.advfn.com/images/uploads/2012/1/11/tzofmslide0008_image016.jpg


Profitability and 2 new NDA filings in 2012
https://images.investorshub.advfn.com/images/uploads/2012/1/11/bnavdslide0018_image036.jpg


MONSTER PIPELINE including a Blockbuster
https://images.investorshub.advfn.com/images/uploads/2012/1/11/hksavslide0006_image012.jpg


Biomedreport Article from Nov 2011
https://www.biomedreports.com/2011111183312/fda-spproval-is-a-game-changer-for-intelgenx.html

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities